On March 18, Sirio Pharma responded to investor inquiries on an interactive platform, stating that the company has nearly completed its international expansion strategy. Sirio has established seven production facilities across China, Europe, and the United States, and is currently building a new manufacturing base in Thailand.
The company emphasized its ability to leverage its global supply chain, optimize production capacity allocation among its facilities, and utilize overseas factories to meet the demands of international clients while mitigating supply chain risks. (Source: Securities Daily)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE